Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.

Abstract:

:Fludarabine is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM) and its combination with cyclophosphamide has been effective in many patients with low-grade lymphoma and chronic lymphocytic leukemia. Based on these data, we administered the combination of fludarabine (25 mg/m2 i.v. day 1-3) and cyclophosphamide (250 mg/m2 i.v. day 1-3,) to 11 patients with WM. Most patients had features indicating poor prognosis including median age of 73 years (range 60-84 years), hemoglobin <100 g/l in 73%, B2-microglobulin >3 mg/l in 64%, symptomatic hyperviscosity in 55% of patients. Only 2 patients were previously untreated, 7 were primary refractory and 2 were relapsing on treatment. The fludarabine-cyclophosphamide combination (FC) was administered every 4 weeks for a total of four courses. Partial response, defined by at least 50% reduction of serum monoclonal protein and of tumor infiltrate at all involved sites was documented in 6 patients (55%) (The median time to response was 4 months). Responding patients demonstrated resolution of disease-related symptoms and correction of anemia. Median time to progression for all patients was 24 months. With a mean follow-up of 28 months, two of six responding patients have progressed so far. The probability of 2-year survival is 70%. This regimen was relatively well tolerated. Complications included neutropenia grade 3 or 4 in 3 patients and thrombocytopenia grade 3 or 4 in 2 patients. There were five infectious episodes including two episodes of neutropenic fever. We conclude that the FC combination appears to be active in patients with WM most of whom were resistant to treatment and had poor prognostic factors. The addition of rituximab to FC requires further investigation.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Dimopoulos MA,Hamilos G,Efstathiou E,Siapkaras I,Matsouka C,Gika D,Grigoraki V,Papadimitriou C,Mitsibounas D,Anagnostopoulos N

doi

10.1080/1042819031000077025

keywords:

subject

Has Abstract

pub_date

2003-06-01 00:00:00

pages

993-6

issue

6

eissn

1042-8194

issn

1029-2403

journal_volume

44

pub_type

临床试验,杂志文章
  • High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.

    abstract::The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1233540

    authors: Muchtar E,Magen H,Gertz MA

    更新日期:2017-06-01 00:00:00

  • Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission.

    abstract::The capacity to generate effective dendritic cells (DC) from adult acute lymphoblastic leukemia (ALL) patients in complete remission (CR) and off-therapy was investigated. Monocyte-derived DC cultured in the presence of granulocyte-macrophage colony-stimulating factor, interleukin (IL)-4 and tumor necrosis factor (TNF...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190601101001

    authors: Maggio R,Peragine N,Calabrese E,De Propris MS,Intoppa S,Della Starza I,Ariola C,Vitale A,Foà R,Guarini A

    更新日期:2007-02-01 00:00:00

  • Gastrointestinal Non-Hodgkin's Lymphoma.

    abstract::The records of 77 patients with gastrointestinal Non-Hodgkin's Lymphoma (GI-NHL) diagnosed from 1972 to 1988 were reviewed. There were 47 male and 30 female patients, median age 56 years (range 20-82 years). Twenty-four patients had stage I disease at presentation, 25 stage II, 8 stage III and 20 stage IV. The primary...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068062

    authors: Stewart AK,Shepherd FA,Goss PE,Warner E,Bailey DJ,Baker MA

    更新日期:1991-01-01 00:00:00

  • Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures.

    abstract:UNLABELLED:We retrospectively analyzed the incidence of thrombotic and infectious complications in relation with the use of central venous catheters (CVCs), in a series of patients with hematological malignancies and low platelet and leucocyte counts. PATIENTS AND METHODS:126 patients with hematological malignancies w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190309178770

    authors: Cortelezzia A,Fracchiolla NS,Maisonneuve P,Moia M,Luchesini C,Ranzi ML,Monni P,Pasquini MC,Lambertenghi-Deliliers G

    更新日期:2003-09-01 00:00:00

  • Rearrangements of the BCL6 gene and chromosome aberrations affecting 3q27 in 54 patients with non-Hodgkin's lymphoma.

    abstract::Chromosome aberrations affecting 3q27 are among the most frequent non-random abnormalities in non-Hodgkin's lymphomas (NHL), especially the diffuse, large cell type. Recently, an association between BCL6 rearrangement and frequent extranodal lesions, rare bone marrow infiltration and a favorable clinical outcome was r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709059687

    authors: Ohshima A,Miura I,Hashimoto K,Takahashi N,Utsumi S,Nimura T,Saito M,Miki T,Hirosawa S,Miura AB

    更新日期:1997-10-01 00:00:00

  • Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.

    abstract::We report results of a randomized, phase III study of ofatumumab versus physicians' choice treatment in patients with bulky fludarabine-refractory chronic lymphocytic leukemia and explore extended versus standard-length ofatumumab treatment. Patients (79 ofatumumab, 43 physicians' choice) completed a median 6 (ofatumu...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,随机对照试验

    doi:10.3109/10428194.2015.1122783

    authors: Österborg A,Udvardy M,Zaritskey A,Andersson PO,Grosicki S,Mazur G,Kaplan P,Steurer M,Schuh A,Montillo M,Kryachok I,Middeke JM,Kulyaba Y,Rekhtman G,Gorczyca M,Daly S,Chang CN,Lisby S,Gupta I

    更新日期:2016-09-01 00:00:00

  • Acute myelogenous leukemia complicated by acute necrotizing ulcerative gingivitis due to Aspergillus terreus.

    abstract::Infections caused by Aspergillus terreus are rare but have been associated with a poor outcome in immunocompromised patients due to frequent resistance to conventional antifungal therapy. This report describes a case of a woman who developed acute necrotizing ulcerative gingivitis (ANUG) due to A. terreus during induc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000060573

    authors: Khoury H,Poh CF,Williams M,Lavoie JC,Nevill TJ

    更新日期:2003-04-01 00:00:00

  • Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.

    abstract::Patients with chemotherapy-refractory non-Hodgkin lymphoma (NHL) have a poor prognosis with a median overall survival (OS) of only 10 months. To investigate the role of radiotherapy (RT) in such patients, we conducted a retrospective review of 17 patients with biopsy-proven refractory NHL who received hyperfractionate...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1719096

    authors: Kim DW,Lee G,Lee H,Mahal AR,Lam MB,Ng AK

    更新日期:2020-06-01 00:00:00

  • Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies.

    abstract::The standard of therapy for the high risk adult neutropenic host being treated with broad spectrum antibiotics for fever has been to continue intravenous antibiotics until neutropenia resolves. We performed a small, limited pilot study to determine if it is safe to switch these patients to oral monotherapy with ciprof...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609054816

    authors: Horowitz HW,Holmgren D,Seiter K

    更新日期:1996-09-01 00:00:00

  • Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.

    abstract::Extranodal natural killer (NK)/T-cell lymphoma is an aggressive lymphoid tumor. Optimal treatment strategies have not yet been fully defined. To explore a more effective treatment, we conducted sequential chemoradiotherapy (SCRT) and evaluated the safety and efficacy. Seventy-eight patients (51 males, 27 females) were...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1108415

    authors: Dong LH,Zhang LJ,Wang WJ,Lei W,Sun X,Du JW,Gao X,Li GP,Li YF

    更新日期:2016-07-01 00:00:00

  • Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway.

    abstract::MDSCs, which are defined as a kind of negatively regulatory cells, could suppress T cell immune response in many tumor-bearing animal models and cancer patients. We supposed that MDSCs also contributed to the impaired antitumor immunity in MDS. Here we demonstrated that STAT3-ARG1 pathway could be a critical signal tr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1817431

    authors: Qi X,Jiang H,Liu P,Xie N,Fu R,Wang H,Liu C,Zhang T,Wang H,Shao Z

    更新日期:2021-01-01 00:00:00

  • Preferential expression of phosphatidylglucoside along neutrophil differentiation pathway.

    abstract::Phosphatidylglucoside (PtdGlc), a new type of glycolipid, was recently identified. We examined PtdGlc expression in normal blood cells and leukemic cells using an anti-PtdGlc monoclonal antibody, DIM-21. Neutrophils, monocytes, HL-60 cells and a subset of cord blood (CB) CD34(+) cells, but not erythroblasts, expressed...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902934928

    authors: Oka S,Nagatsuka Y,Kikuchi J,Yokote T,Hirabayashi Y,Hanafusa T,Ozawa K,Muroi K

    更新日期:2009-07-01 00:00:00

  • Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.

    abstract::The occurrence of unexplained peripheral blood cytopenia, particularly neutropenia, has been recently reported after rituximab. Its prevalence may be underestimated since it may occur late after treatment. This study analysed all cases of unexplained delayed-onset peripheral blood cytopenia of WHO grade II - IV occurr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500473113

    authors: Cattaneo C,Spedini P,Casari S,Re A,Tucci A,Borlenghi E,Ungari M,Ruggeri G,Rossi G

    更新日期:2006-06-01 00:00:00

  • Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.

    abstract::The aim of the present study was to evaluate the feasibility and response of the Dexa-BEAM regimen as a salvage therapy followed by high-dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBCST) in responding patients with high-grade relapsed or resistant aggressive non-Hodgkin's lymphoma (NHL)....

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199909058430

    authors: Reiser M,Josting A,Dias Wickramanayake P,Draube A,Scheid C,Tesch H,Wolf J,Diehl V,Engert A

    更新日期:1999-04-01 00:00:00

  • Autologous Bone-Marrow Transplantation in Acute Lymphoblastic Leukaemia: 1980-89.

    abstract::The outcome of conventional therapy in adult acute lymphoblastic leukaemia (ALL) is disappointing. Allogeneic bone-marrow transplantation may give improved results but has only limited applicability because of the lack of a suitable donor in most patients. We have therefore investigated intensive chemotherapy and chem...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009042474

    authors: Mcmillan AK,Gribben JG,Linch DC,Anderson C,Richards JD,Goldstone AH

    更新日期:1990-01-01 00:00:00

  • Cell cycle-independent down-regulation of BCL-2 protein expression in differentiating HL-60 cells.

    abstract::To understand the relationship between bcl-2 protein expression and the cell cycle during the processes of differentiation, we examined bcl-2 protein levels expressed during cell cycle phases in differentiating HL-60 human leukemia cells by using a two-color flow cytometric method. In exponentially proliferating HL-60...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009148859

    authors: Kumakura S,Ishikura H,Tsumura H,Nakashima A,Sato Y,Kobayashi S

    更新日期:2000-01-01 00:00:00

  • A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.

    abstract::Following the introduction of the WHO classification of chronic myeloproliferative disorders (MPDs), after approximately 5 years, a critical reappraisal appears to be warranted. Retrospective clinico-pathological evaluations conducted in the meantime, as well as the detection of new biomarkers, may aid in testing the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190500331329

    authors: Thiele J,Kvasnicka HM

    更新日期:2006-03-01 00:00:00

  • Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.

    abstract::A clinical case of patient with a simultaneous gastrointestinal stromal tumors (GIST) and MALT lymphoma in relapse is presented. Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190412331272712

    authors: Bompas E,Velay B,Blay JY

    更新日期:2004-11-01 00:00:00

  • Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.

    abstract::The cytokine IL-6 has been proposed as an autocrine growth factor in multiple myeloma, and is also required for stimulation of immunoglobulin production and secretion in normal plasma cells and myeloma cells. In this study, we showed that secreted IL-6 is detectable by Western blot analysis in a panel of lymphoid and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209067610

    authors: Shiao RT,McLeskey SB,Khera SY,Wolfson A,Freter CE

    更新日期:1996-04-01 00:00:00

  • Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene.

    abstract::Donor T cells have a critical role in promoting engraftment after allogeneic bone marrow transplantation (BMT), but also cause graft versus host disease (GVHD). Ex vivo T cell depletion has been an effective strategy to reduce GVHD but has been associated with impaired alloengraftment and host immunity. Using an MHC-m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000016041

    authors: Drobyski WR,Gendelman M

    更新日期:2002-10-01 00:00:00

  • Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.

    abstract::This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+, CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049659

    authors: Witzig TE,Weitz JJ,Lundberg JH,Tefferi A

    更新日期:1994-06-01 00:00:00

  • Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma.

    abstract::Polymorphisms in detoxification enzymes of the glutathione S-transferase (GST) family have been associated with risk and prognosis of several cancer types. We studied deletions of GSTM1 and GSTT1, and the GSTP1 Ile(105)Val polymorphism in 89 patients with follicular lymphoma (FL). Patients with a GSTM1 or GSTT1 deleti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190601158647

    authors: Hohaus S,Mansueto G,Massini G,D'Alo F,Giachelia M,Martini M,Larocca LM,Voso MT,Leone G

    更新日期:2007-03-01 00:00:00

  • Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia.

    abstract::Speed of response to therapy predicts outcome in childhood lymphoblastic leukaemia. This observation has been made studying both blood and bone marrow in children on widely differing treatment regimens from the 1970s to the present day. It appears to be independent of other classical prognostic factors such as age and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057609

    authors: Lilleyman JS

    更新日期:1998-11-01 00:00:00

  • Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1.

    abstract::Rituximab is a CD20-targeted monoclonal antibody widely used in the treatment of B-cell lymphoma. Previously, we have shown that Epstein-Barr virus (EBV) latent membrane protein-1 (LMP1) increases chemoresistance in malignant cancer cells. In this study we examined the effects of LMP1 on the response of B-cell lymphom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.659736

    authors: Kim JH,Kim WS,Park C

    更新日期:2012-08-01 00:00:00

  • Detection of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia by Analysis of Gene Rearrangements and Correlation with Early Relapses.

    abstract::While more than 75% of the adult patients with acute lymphoblastic leukemia (ALL) achieve a complete remission after treatment with intensive chemotherapy, about 40% of them relapse within five years. These relapses are probably due to residual leukemic cells. Gene rearrangements are used as markers of clonality and t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068105

    authors: Knauf WU,Ho AD,Heger G,Hoelzer D,Hunstein W,Thiel E

    更新日期:1991-01-01 00:00:00

  • Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.

    abstract::This study was designed to evaluate the efficacy and toxicity of dose intensifying DHAP (dexamethasone, cytarabine and cisplatin) salvage chemotherapy by adding mitoxantrone with GM-GSF support in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). From March 1992 to January 1995, 22 patients with inter...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/10428199909169617

    authors: Haq R,Sawka CA,Franssen E,Berinstein NL

    更新日期:1999-11-01 00:00:00

  • Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.

    abstract::Information on the use of hypomethylating agents (HMAs) as a pre-transplant cytoreductive therapy in MDS is limited. We retrospectively evaluated outcomes of 172 adult MDS patients, who underwent allogeneic hematopoietic stem cell transplantation between January 2000 and December 2016. Patients were divided into three...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1605070

    authors: Modi D,Kim S,Singh V,Ayash L,Alavi A,Ratanatharathorn V,Uberti JP,Deol A

    更新日期:2019-11-01 00:00:00

  • Three cases of primary cutaneous lymphoblastic lymphoma: microarray-based comparative genomic hybridization and gene expression profiling studies with review of literature.

    abstract::Lymphoblastic lymphoma (LBL) is a neoplasm of precursor B- or T-lymphocytes, and primary skin involvement is uncommon. The aim of the study was to review all reported primary cutaneous (PC)-LBLs and to examine three new cases to better characterize this neoplasm. Two of our patients showed a pre-B phenotype (PC-B-LBL)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.618233

    authors: Vezzoli P,Novara F,Fanoni D,Gambini D,Balice Y,Venegoni L,Paulli M,Crosti C,Berti E

    更新日期:2012-10-01 00:00:00

  • Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.

    abstract::Thrombopoietin (TPO) has been successfully used to stimulate megakaryocyte progenitor proliferation and platelet production both in vitro and in vivo. We and other investigators have found that TPO also stimulates normal marrow colony-forming unit granulocyte-macrophage (CFU-GM) and burst-forming unit-erythroid (BFU-E...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809057541

    authors: Ferrajoli A,Talpaz M,Kurzrock R,Harris D,Van Q,Estey EH,Estrov Z

    更新日期:1998-07-01 00:00:00

  • Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

    abstract::New therapies for relapsing/refractory Hodgkin lymphoma (R/R HL) and R/R systemic anaplastic large-cell lymphoma (sALCL) have emerged. This study captured utility values for R/R HL and sALCL to support economic evaluation. Health state "vignettes" were developed describing states associated with R/R HL and sALCL: trea...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.970542

    authors: Swinburn P,Shingler S,Acaster S,Lloyd A,Bonthapally V

    更新日期:2015-06-01 00:00:00